Julie Brahmer's guest appearances

Julie Brahmer

Research To Practice | Oncology Videos

GRACEcast Lung Cancer Video

GRACEcast Lung Cancer Audio

Ross Camidge

Suresh Ramalingam

Jared Weiss

Andrew X

Axel Grothey

Alan P Venook

Zev Wainberg

Yelena Y Janjigian

Tanios Bekaii-Saab

Philip A Philip

Eileen M O’Reilly

E Gabriela Chiorean

Talia Golan

Emmanuel S Antonarakis

Johanna Bendell

OwlTail

Edward Garon

Ramaswamy Govindan

Hossein Borghaei

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Part 2: A roundtable discussion featuring Borghaei, Brahmer, Garon and Govindan.  Genomic profiling for patients with metastatic NSCLC; role of liquid biopsy (00:00) Therapeutic approach for patients with NSCLC with no targetable mutations (10:02) Case (Dr Deutsch): A woman in her late 60s with metastatic squamous cell carcinoma of the lung and a high PD-L1 tumor proportion score (TPS) of 60% initially treated with pembrolizumab monotherapy receives carboplatin/paclitaxel and maintenance pembrolizumab upon disease progression (21:32) Case (Dr Picton): A man in his mid-80s and previous smoker receives carboplatin/paclitaxel/pembrolizumab as first-line therapy for metastatic squamous cell carcinoma of the lung (27:35) Selection of second-line therapy for patients with metastatic nonsquamous NSCLC; benefits and risks with the addition of ramucirumab to docetaxel (32:17) Perspective on the use of bevacizumab or ramucirumab in combination with an immune checkpoint inhibitor and chemotherapy for metastatic NSCLC (37:03) Case (Dr Martins): A man in his early 70s and previous smoker with metastatic nonsquamous NSCLC develops diarrhea with bleeding after receiving first-line pembrolizumab (45:42) Screening and clinical care of patients with lung cancer during the COVID-19 pandemic (48:59) Case (Dr Picton): A woman in her early 50s with metastatic squamous NSCLC with a BRAF tumor mutation receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pemetrexed/pembrolizumab and develops immune-related colitis (55:18) Management of metastatic NSCLC with targetable EGFR mutations (1:01:56) Case (Dr Deutsch): A woman in her late 40s and never smoker with metastatic adenocarcinoma of the lung with an EGFR tumor mutation develops a T790M mutation 2 years after treatment with erlotinib and bevacizumab on a clinical trial (1:11:18)   CME information and select publications

Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer — Part 2: A roundtable discussion featuring Borghaei, Brahmer, Garon and Govindan. <ul> <li>Genomic profiling for patients with metastatic NSCLC; role of liquid biopsy (00:00)</li> <li>Therapeutic approach for patients with NSCLC with no targetable mutations (10:02)</li> <li>Case (Dr Deutsch): A woman in her late 60s with metastatic squamous cell carcinoma of the lung and a high PD-L1 tumor proportion score (TPS) of 60% initially treated with pembrolizumab monotherapy receives carboplatin/paclitaxel and maintenance pembrolizumab upon disease progression (21:32)</li> <li>Case (Dr Picton): A man in his mid-80s and previous smoker receives carboplatin/paclitaxel/pembrolizumab as first-line therapy for metastatic squamous cell carcinoma of the lung (27:35)</li> <li>Selection of second-line therapy for patients with metastatic nonsquamous NSCLC; benefits and risks with the addition of ramucirumab to docetaxel (32:17)</li> <li>Perspective on the use of bevacizumab or ramucirumab in combination with an immune checkpoint inhibitor and chemotherapy for metastatic NSCLC (37:03)</li> <li>Case (Dr Martins): A man in his early 70s and previous smoker with metastatic nonsquamous NSCLC develops diarrhea with bleeding after receiving first-line pembrolizumab (45:42)</li> <li>Screening and clinical care of patients with lung cancer during the COVID-19 pandemic (48:59)</li> <li>Case (Dr Picton): A woman in her early 50s with metastatic squamous NSCLC with a BRAF tumor mutation receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pemetrexed/pembrolizumab and develops immune-related colitis (55:18)</li> <li>Management of metastatic NSCLC with targetable EGFR mutations (1:01:56)</li> <li>Case (Dr Deutsch): A woman in her late 40s and never smoker with metastatic adenocarcinoma of the lung with an EGFR tumor mutation develops a T790M mutation 2 years after treatment with erlotinib and bevacizumab on a clinical trial (1:11:18)</li> </ul> <a href="http://m.researchtopractice.com/LungCancerSummit20/Roundtable/Video?playlistIndex=0#t=0m0s" rel="nofollow" target="_blank"> CME information and select publications</a>

Lung Cancer | Roundtable Discussion with Drs Hossein Borghaei, Julie Brahmer, Edward Garon and Ramaswamy Govindan 

Greg Riely

Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.

Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.

Case Discussion with Experts, Drs. Julie Brahmer and Greg Riely: Case 1 (audio)